Author Archives : Editorial Team

Home  >>  Author : Editorial Team

DKFZ: Mechanism of action of a diabetes drug differs between males and females

On July 11, 2018, Posted by , In News, By , , With Comments Off on DKFZ: Mechanism of action of a diabetes drug differs between males and females

Most diabetes medications do not attack the cause of the disease. Glitazones are different: they improve insulin sensitivity and can promote the conversion of unhealthy white adipose tissue into fat-burning beige adipocytes. However, due to their side effects, they are hardly used. Scientists from the German Cancer Research Center are…

DKFZ: Brain cancer – Typical mutation in cancer cells stifles immune response

On July 11, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ: Brain cancer – Typical mutation in cancer cells stifles immune response

The exchange of a single amino acid building block in a metabolic enzyme can lead to cancer. In addition, it can impair the immune system, scientists from the German Cancer Research Center (DKFZ), the University Hospitals in Mannheim and Heidelberg, and the German Cancer Consortium now report. It thus blocks…

New member: Welcome in our cluster to HITS – Heidelberg Institute for Theoretical Studies

On July 11, 2018, Posted by , In News, By , With Comments Off on New member: Welcome in our cluster to HITS – Heidelberg Institute for Theoretical Studies

We are happy to welcome in our cluster the Heidelberg Institute for Theoretical Studies: The Heidelberg Institute for Theoretical Studies (HITS) was established in 2010 by the physicist and SAP co-founder Klaus Tschira (1940-2015) and the Klaus Tschira Foundation as a private, non-profit research institute. HITS conducts basic research in…

Boehringer Ingelheim Championing Early-Stage Life Science Entrepreneur Innovation in Heidelberg

On July 10, 2018, Posted by , In Press Releases, By ,, , With Comments Off on Boehringer Ingelheim Championing Early-Stage Life Science Entrepreneur Innovation in Heidelberg

Heidelberg 10.07.2018 BioRN as cross-cutting representative of the life science community supported Boehringer Ingelheim in the organisation, promotion and execution of this successful event. Open panel discussion during the Summer Networking Reception. Partnerships with early-stage companies often spark some of the most innovative research and development collaborations in the healthcare…

New member: Welcome in our cluster to Drees & Sommer

On July 10, 2018, Posted by , In News, By , With Comments Off on New member: Welcome in our cluster to Drees & Sommer

We are happy to welcome in our cluster Drees & Sommer. Drees & Sommer is an innovative partner for consulting, planning, construction and operation. For more than 45 years, the company has been supporting public- and private-sector owners and investors in all aspects of real estate. Managed by partners and…

New member: Welcome in our cluster to ERA Consulting

On July 5, 2018, Posted by , In News, By , With Comments Off on New member: Welcome in our cluster to ERA Consulting

We are happy to welcome in our cluster ERA Consulting. The ERA Consulting Group is one of the longest established and most experienced regulatory affairs and product development consulting groups serving the biopharmaceutical industry. “Our expertise covers quality, nonclinical and clinical aspects, both from the regulatory and development strategy perspective….

EMBL: Combining antibiotics changes their effectiveness

On July 5, 2018, Posted by , In News, By , With Comments Off on EMBL: Combining antibiotics changes their effectiveness

The effectiveness of antibiotics can be altered by combining them with each other, non-antibiotic drugs or even with food additives, EMBL researchers show. Depending on the bacterial species, some combinations stop antibiotics from working to their full potential whilst others begin to defeat antibiotic resistance, report EMBL researchers and collaborators…

Viscofan BioEngineering: Phase-I-trial approved for novel stem cell therapy for patients with ischemic cardiomyopathy

On July 4, 2018, Posted by , In News, By ,, , With Comments Off on Viscofan BioEngineering: Phase-I-trial approved for novel stem cell therapy for patients with ischemic cardiomyopathy

Viscofan BioEngineering, the biomedical business unit of the world market leader for collagenous sausage casings Viscofan announced today that the Spanish Agency for Medicines (AEMPS) has given green light to carry out a clinical phase-I-trial with Viscofan BioEngineering’s first product for regenerative medicine. The novel therapy consisting of stem cells…

BioRN Lounge: Dr. Juergen Gamer talked about Apogenix attractive immuno-oncology pipeline.

On June 27, 2018, Posted by , In Press Releases, By , , With Comments Off on BioRN Lounge: Dr. Juergen Gamer talked about Apogenix attractive immuno-oncology pipeline.

Heidelberg, 27.06.2018 BioRN Lounge: Dr. Juergen Gamer talked about “TNF Superfamily Receptor Modulators – Innovative Immuno-oncology Therapeutics” Once again, the BioRN Lounge was the occasion for the life science companies as well for scientists from our research institutes, to meet and chat about latest news and achievements. The BioRN Lounge…

DKFZ/Heidelberg University: New therapy makes blood cancer cells visible for the immune system

On June 27, 2018, Posted by , In News, By , , With Comments Off on DKFZ/Heidelberg University: New therapy makes blood cancer cells visible for the immune system

Chronic lymphocytic leukemia (CLL) is the most common type of blood cancer in adults. It can be treated with chemotherapy and oral drugs but this treatment cannot cure the cancer completely. Although the human immune system is capable of fighting the cancer cells, it often fails to notice them early…